PTIX — Proxy Statement Filing Deadline
Sep 1, 2025, 5:00:00 AM UTC
Summary
Protagenic Therapeutics, Inc. is set to file a proxy statement by September 1, 2025, related to a stockholder meeting. The agenda includes proposals for the approval of a share conversion pertaining to newly issued Preferred Stock and a change of control under Nasdaq Listing Rules following the company's acquisition of Phytanix Bio. The planned share exchange agreement aims to issue new common and preferred stock, effectively altering the capital structure post-acquisition. Such a conversion is expected to position Protagenic favorably in the market and is critical for compliance with Nasdaq regulations, with potential implications on shareholder value and dilution.
Company
PROTAGENIC THERAPEUTICS INC (PTIX)NASDAQ — Healthcare: Services, Biotechnology: Services-Business Services Nec
www.protagenic.comSimilar Events
Deadline for Preliminary Proxy Statement Filing
Cero Therapeutics Holdings, Inc. has a deadline of May 31, 2025, to file a preliminary Proxy Statement with the SEC. This filing seeks stockholder consent for the issuance of Conversion Shares related to its Series D convertible preferred stock, which was part of a recent private placement of up to $8 million. As of April 22, 2025, the company successfully raised approximately $5 million by selling 6,250 shares of this preferred stock. The Series D shares are convertible into common stock at a fixed price of $0.78, and if shareholder approval is not obtained by the deadline, Cero Therapeutics plans to proceed with the filing as required.
Proxy Statement FilingDeadline for Proxy Statement Submission
Protagenic Therapeutics, Inc. is set to file a proxy statement with the Securities and Exchange Commission by September 1, 2025. This filing relates to proposals that include a conversion of certain preferred stock into common stock and a change of control under Nasdaq regulations. The proposals follow the company's recent acquisition of Phytanix Bio, which adds to Protagenic's asset base and reflects on its strategic intent to diversify and strengthen its market positioning. Shareholder approval will be sought in a forthcoming meeting, emphasizing the financial implications of these restructuring initiatives.
Submission of Proxy StatementDeadline for Definitive Proxy Statement Filing
Cero Therapeutics Holdings, Inc. is expected to file its definitive proxy statement by June 30, 2025, following its preliminary filing. This filing is part of the company's obligations related to a recent private placement of securities, including Series D convertible preferred stock, aimed at raising a total of $8 million from accredited investors. As of April 22, 2025, the company closed on the first tranche, generating approximately $5 million in proceeds. This funding will support compliance efforts with Nasdaq listing requirements and financial stability efforts after prior capital raises totaling about $6.4 million earlier in 2025.
Definitive Proxy Statement FilingFiling Deadline for Registration Statement
Lexeo Therapeutics, Inc. is set to file a registration statement by June 27, 2025, for the resale of shares and warrants in connection with a recently announced private placement transaction. The private placement, which was entered into on May 27, 2025, involves the sale of approximately 20.8 million shares of common stock and warrants, aiming to raise around $80 million in gross proceeds. The company plans to utilize these proceeds for working capital and general corporate purposes. The Placement, managed by J.P. Morgan and Oppenheimer & Co., is expected to close shortly after the filing deadline, contingent upon customary closing conditions. This event marks an important step for Lexeo as it provides access to funds that could support its operational initiatives.
Filing Registration Statement